marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-12-2024
Artelo Biosciences Balance Sheet 2011-2024 | ARTL
Annual Balance Sheet Artelo Biosciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-6.82 M | -12.1 M | -2.14 M | -4.42 M | -337 K | -573 K | -3.59 K | -17 K | -14.7 K | - | - | - | |
Long Term Debt |
- | 23 K | 57 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
23 K | 40 K | 31 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
1.29 M | 998 K | 1.03 M | 501 K | 1.02 M | 532 K | 29.4 K | 17.4 K | 1.74 K | - | - | - | - |
Total Liabilities |
1.29 M | 1.02 M | 1.08 M | 502 K | 1.02 M | 532 K | 29.4 K | 17.4 K | 1.74 K | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-40.3 M | -31 M | -20.9 M | -9.47 M | -4.81 M | -2.64 M | -295 K | -60.2 K | -30.5 K | -15.3 K | - | - | - |
Total Assets |
13 M | 20.4 M | 28.3 M | 4.38 M | 6.48 M | 397 K | 574 K | 3.59 K | 17 K | 14.7 K | - | - | - |
Cash and Cash Equivalents |
2.82 M | 6.89 M | 12.2 M | 5.78 M | 4.42 M | 337 K | 573 K | 3.59 K | 17 K | 14.7 K | - | - | - |
Book Value |
11.8 M | 19.4 M | 27.2 M | 3.87 M | 5.46 M | -135 K | 545 K | -13.8 K | 15.3 K | 14.7 K | - | - | - |
Total Shareholders Equity |
11.8 M | 19.4 M | 27.2 M | 8.44 M | 5.46 M | -135 K | 545 K | -13.8 K | 15.3 K | 14.7 K | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Artelo Biosciences
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
78 K | - | - | - | - | - | 15 K | 23 K | 32 K | - | - | 57 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
775 K | 1.03 M | 817 K | 1.29 M | 921 K | 609 K | 840 K | 1.02 M | 512 K | 567 K | 924 K | 1.08 M | 593 K | - | 718 K | - | 501 K | - | - | - | - | - | - | - | - | - | - | - | - | 342 K | 32.9 K | 10 K | 17.4 K | 17.4 K | 17.4 K | 3.3 K | 1.74 K | 1.74 K | 1.74 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-46.4 M | -45.2 M | -42.8 M | -40.3 M | -37.2 M | -34.8 M | -33.2 M | -31 M | -27.7 M | -25.4 M | -22.9 M | -20.9 M | -16.9 M | -15 M | -19.5 M | -10.9 M | -9.47 M | -9.47 M | -9.47 M | -6.12 M | -4.81 M | -4.81 M | -4.81 M | -3.2 M | -2.64 M | -2.64 M | -2.64 M | -572 K | -295 K | -295 K | -572 K | -69.7 K | -60.2 K | -60.2 K | -60.2 K | -45.7 K | -30.5 K | -30.5 K | -30.5 K | - | -15.3 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
7.14 M | 8.33 M | 10.4 M | 13 M | 15.5 M | 16.9 M | 18.5 M | 20.4 M | 22.4 M | 24.4 M | 26.7 M | 28.3 M | 12.6 M | 12.3 M | 29 M | 9.54 M | 4.38 M | 4.38 M | 4.38 M | 5.55 M | 6.48 M | 6.48 M | 6.48 M | 165 K | 397 K | 397 K | 397 K | 430 K | 574 K | 574 K | 430 K | 3.59 K | 3.59 K | 3.59 K | 3.59 K | 3.97 K | 17 K | 17 K | 17 K | - | 14.7 K | 14.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
4.36 M | 881 K | 1.2 M | 2.82 M | 2.64 M | 5.72 M | 6.92 M | 6.89 M | 7.14 M | 12.1 M | 10.4 M | 12.2 M | 6.59 M | 6.31 M | 14 M | 5.78 M | 2.14 M | 2.14 M | 7.39 M | 3.37 M | 4.42 M | 4.42 M | 3.37 M | 115 K | 337 K | 337 K | 115 K | 412 K | 573 K | 573 K | 412 K | 3.59 K | 3.59 K | 3.59 K | 3.59 K | 3.97 K | 17 K | 17 K | 3.97 K | 14.2 K | 14.7 K | 14.7 K | 29.9 K | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
6.36 M | 7.3 M | 9.54 M | 11.8 M | 14.6 M | 16.3 M | 17.6 M | 19.4 M | 21.9 M | 23.8 M | 25.8 M | 27.2 M | 12 M | 12.3 M | 28.3 M | 9.54 M | 3.88 M | 4.38 M | 4.38 M | 5.55 M | 6.48 M | 6.48 M | 6.48 M | 165 K | 397 K | 397 K | 397 K | 430 K | 574 K | 232 K | 397 K | -6.46 K | -13.8 K | -13.8 K | -13.8 K | 671 | 15.3 K | 15.3 K | 15.3 K | - | 14.7 K | 14.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
6.36 M | 7.3 M | 9.54 M | 11.8 M | 14.6 M | 16.3 M | 17.6 M | 19.4 M | 21.9 M | 23.8 M | 25.8 M | 27.2 M | 11.5 M | 12.8 M | 13.3 M | 8.44 M | 9.05 M | 9.05 M | 9.05 M | 4.96 M | 4.96 M | 4.96 M | 4.96 M | -475 K | -475 K | -475 K | -475 K | 294 K | 545 K | 545 K | 294 K | -6.46 K | -13.8 K | -13.8 K | -13.8 K | 671 | 15.9 K | 15.3 K | 15.3 K | - | 14.7 K | 14.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency